share_log

Novo-Nordisk A/S | 6-K: Awiqli® (Once-Weekly Basal Insulin Icodec) Recommended for Approval for the Treatment of Diabetes by the European Regulatory Authorities

SEC announcement ·  Mar 22 06:11
Summary by Moomoo AI
Novo Nordisk A/S announced on March 21, 2024, that its diabetes treatment, Awiqli® (once-weekly basal insulin icodec), has been recommended for approval by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). The recommendation is based on the ONWARDS phase 3a clinical trial programme, which demonstrated Awiqli®'s efficacy in reducing blood sugar levels and the frequency of hypoglycaemic events in adults with type 1 and type 2 diabetes. The treatment, which reduces the number of required insulin injections from daily to weekly, is expected to receive final marketing authorisation from the European Commission within two months. Novo Nordisk, a global healthcare leader headquartered in Denmark, is optimistic about Awiqli® becoming the preferred insulin treatment for type 2 diabetes patients initiating insulin therapy.
Novo Nordisk A/S announced on March 21, 2024, that its diabetes treatment, Awiqli® (once-weekly basal insulin icodec), has been recommended for approval by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). The recommendation is based on the ONWARDS phase 3a clinical trial programme, which demonstrated Awiqli®'s efficacy in reducing blood sugar levels and the frequency of hypoglycaemic events in adults with type 1 and type 2 diabetes. The treatment, which reduces the number of required insulin injections from daily to weekly, is expected to receive final marketing authorisation from the European Commission within two months. Novo Nordisk, a global healthcare leader headquartered in Denmark, is optimistic about Awiqli® becoming the preferred insulin treatment for type 2 diabetes patients initiating insulin therapy.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more